Valence ロゴ
人気
ログイン

ウォッチリストに追加

Charles River Laboratorie...

NYSE: CRL · リアルタイム株価 · USD
279.19
-7.45 (-2.60%)
終値時点： Aug 18, 2026, 3:59 PM

Charles River Laboratories International Inc. (CRL) Stock Price, Analysis & Data

-2.60%
買気配n/a
時価総額13.45B
売上高（TTM）4B
純利益（TTM）-238.46M
ベータ1.38
EPS（TTM）-4.82
PER（TTM）n/a
予想PER22.01
PBR（TTM）4.69
PSR（TTM）3.33
Earnings DateNov 4, 2026
売気配n/a
出来高595,764
平均出来高（20日）894,698
始値286.40
前日終値286.64
当日レンジ279.11 - 289.60
52週レンジ144.26 - 289.60
アナリストBuy
目標株価300 (7.45%)
配当n/a
権利落ち日n/a

CRLについて

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research a...

[続きを読む]
業種 Diagnostics & Research
セクター Healthcare
IPO日 Jun 23, 2000
従業員数 18,300
上場取引所 NYSE
ティッカー CRL
ウェブサイト https://www.criver.com
企業情報の全文

業績

2025年のCharles River Laboratories Internationalの売上高は4.02Bで、前年の4.05Bから-0.85%の減少でした。 利益は-144.34Mで、-1,501.75%の減少でした。

財務諸表

アナリスト予想

14件のアナリスト評価によると、CRL株の平均レーティングは「Buy」です。12か月後の目標株価は300で、直近株価から7.45%の上昇余地となります。

株価予想

決算サプライズ

Charles River Laboratories InternationalはAug 5, 2026に四半期決算を発表しました：
  • 売上高は $1B で、予想を下回りました $0, うち -2.72% の前年比減少.
  • EPSは 3.02 で、予想を上回りました 0.28, うち -3.21% の前年比減少.

    • 次回決算発表

    Charles River Laboratories International Inc.の決算発表予定日は Nov 4, 2026, 寄り付き前の予定です。
    アナリストの売上高予想は ... アップグレード
    news image

    2日前 · StockStory

    1 Mid-Cap Stock with Exciting Potential and 2 Facing Challenges

    Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe wit...

    news image

    4日前 · StockStory

    5 Insightful Analyst Questions From Charles River Laboratories’s Q2 Earnings Call

    Charles River Laboratories’ second quarter results were shaped by recovering biopharmaceutical demand and the impact of portfolio streamlining. Management highlighted that the rebound was most evident...

    news image

    6日前 · Motley Fool

    Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript

    Organic revenue returned to growth as biopharmaceutical demand strengthened.

    news image

    1週間前 · Zacks

    CRAI Jumps 20% in 3 Months as Demand Broadens Across Key Practices

    CRAI's 20% three-month gain is backed by broader demand, a stronger project pipeline and higher fiscal 2026 revenue guidance, but costs remain a drag.

    news image

    1週間前 · Zacks

    International Markets and Charles River (CRL): A Deep Dive for Investors

    Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

    2ページ中1ページ